NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017Mary B. Daly, Susan Darlow, Judy E. Garber et al.|Journal of the National Comprehensive Cancer Network|2016Cited by 660
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and <i>BRCA1</i>/<i>2</i> Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Melinda L. Telli, James M. Ford, Kristin C. Jensen et al.|Journal of Clinical Oncology|2015Cited by 226
92 High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancerAlexander P. Gottlieb, Jennifer L. Guerriero, Gregory J. Baker et al.|Regular and Young Investigator Award Abstracts|2024Cited by 1